EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic

TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product.Rigorous

AccesswireAug 16, 2023 09:30 ET

EV Biologics Launches Excyte With $100M Valuation

EV Biologics (OTCPK:YECO) is trading 41% higher after it said on Monday it had launched a subsidiary Excyte, Inc, with $100M valuation. The company said Excyte had already raised $500,000 of its $2.5M

Seeking AlphaAug 15, 2022 15:53 ET

EV Biologics Launches Excyte With $100 Million Valuation

TAMPA, FL / ACCESSWIRE / August 15, 2022 / EV Biologics Corp, OTC Pink: YECO, today announced that it has launched Excyte, Inc., a wholly owned subsidiary, with $100 Million valuation.Excyte has alrea

AccesswireAug 15, 2022 09:05 ET

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

HOUSTON, TX / ACCESSWIRE / May 17, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has signed a Manufacturing Services Agreement (MSA) with Lonza for development of stem/progenitor ce

AccesswireMay 17, 2022 12:09 ET

EV Biologics Isolates Primary Cells for Nanoparticle Production & Accelerated Cell Line Development

TAMPA, FL / ACCESSWIRE / April 12, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has succeeded in isolating primary progenitor cells from tissue using a xeno-free process.The Compan

AccesswireApr 12, 2022 09:06 ET

EV Biologics Updates on FINRA Filings

NASHVILLE, TN / ACCESSWIRE / March 9, 2022 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with the latest information about its submitted FINRA applications for name change and NFT div

AccesswireMar 9, 2022 09:06 ET